Off-label use means a doctor prescribes a medication that has been approved by a regulatory agency but for a purpose, patient population, or dosage that was not part of the original approval. It is completely legal, surprisingly common, and in many cases supported by good clinical evidence. The practice exists because drug approvals are narrow by design: a pharmaceutical company typically seeks approval for one specific condition in one specific group, even when the drug turns out to help with other problems, too. Understanding why off-label prescribing happens, when it works well, and when it carries extra risk gives you a much clearer picture of how modern medicine actually functions.
How Common Is Off-Label Prescribing
Off-label use is not a fringe practice. Estimates vary widely depending on the medical setting and patient population, but large reviews consistently find that a substantial share of all prescriptions fall outside a drug’s approved label. In primary care, some studies put the figure around one in five prescriptions. In hospitals and specialty clinics, the rate can climb much higher.
Children are the group most affected. A systematic review covering 31 studies found off-label prescription rates ranging from about 3% to 95%, depending on the setting and how “off-label” was defined. Pooling the data, the overall estimated rate was roughly 31%. Younger children face the highest rates: infants under one year old had about a 52% chance of receiving an off-label prescription, while the probability dropped to around 29% by age twenty, declining about 3% for every additional year of age.1National Institutes of Health / PubMed Central. Off-Label Medication use in Children, More Common than We Think: A Systematic Review of the Literature
The reason pediatric rates are so high is straightforward: drug companies rarely run clinical trials on young children. The trials needed for regulatory approval are expensive, ethically complex in minors, and commercially uncertain. As a result, many drugs that are well-studied and approved for adults simply never get an official pediatric label, even when pediatricians have been using them safely for years. Both the EU and the US have introduced legislation aimed at encouraging more pediatric trials, but progress has been slow.2PubMed. Regulating pediatric off-label uses of medicines in the EU and USA: challenges and potential solutions
Why Doctors Prescribe Medications Off-Label
There is no single reason. Off-label prescribing arises from a mismatch between how drug regulation works and how medical knowledge accumulates. Regulatory agencies approve a drug for one condition based on the evidence submitted by the manufacturer. But once the drug is on the market and widely used, doctors, researchers, and patients begin to notice it helps with other conditions, too. Published studies and clinical experience build up, sometimes over decades, and the drug becomes a standard part of treatment for conditions it was never formally approved for. The manufacturer, meanwhile, has little financial incentive to pursue a new approval for an old drug, especially if the patent has expired.
Psychiatry is a field where off-label use is deeply embedded. Many psychotropic medications are prescribed for conditions or age groups outside their approved labels. An antidepressant approved for major depression might be prescribed for anxiety, insomnia, or chronic pain. An antipsychotic approved for schizophrenia might be used at lower doses for agitation in elderly patients with dementia. In many of these cases, the evidence base is reasonable, but the formal regulatory stamp is simply absent.
Other common drivers include:
- Rare diseases: When a condition affects only a small number of people, there may be no approved treatment at all, and off-label use of an existing drug becomes the only viable option.
- Cancer treatment: Tumors with specific genetic mutations may respond to a drug approved for a different cancer type that targets the same mutation.
- Pediatric medicine: As described above, drugs proven safe and effective in adults are routinely used in children without formal pediatric approval.
- Exhausted options: When a patient has tried and failed every approved therapy, a doctor may turn to off-label alternatives backed by emerging evidence.
The Semaglutide Example
Few recent cases illustrate off-label prescribing as vividly as the surge in semaglutide use for weight loss. Semaglutide was originally approved under the brand name Ozempic for type 2 diabetes. A higher-dose version, Wegovy, was later approved specifically for weight management. But demand exploded, and many people began obtaining the diabetes-labeled formulation (Ozempic) off-label for weight loss, contributing to widespread shortages.
A large survey of real-world Ozempic users found that about 72% reported taking it specifically for weight loss alone, with an additional 20% citing both weight loss and diabetes control. Only about 8% used it exclusively for blood sugar management without any weight-loss intent.3PubMed Central. Real-World Off-Label Use of Semaglutide for Weight Reduction: User Behavior, Effectiveness, and Satisfaction In Denmark, prescribing data told a similar story from the supply side: the share of new semaglutide (Ozempic) users who actually had a type 2 diabetes diagnosis on record dropped from 99% in 2018 to just 67% in 2022, before rebounding to 87% in 2023 as regulators and pharmacies tightened oversight.4PubMed Central. Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss
The semaglutide case highlights both the appeal and the complications of off-label prescribing. The weight-loss benefits were real and backed by clinical trial data (which eventually led to the separate Wegovy approval). But the off-label rush created drug shortages for diabetic patients who depended on Ozempic for blood sugar control, raised insurance-coverage headaches, and put some users in a gray area where their doctors were prescribing a drug for a purpose the insurer would not reimburse.
Off-Label Targeted Therapy in Oncology
Cancer treatment is one of the fields where off-label prescribing carries the strongest scientific rationale. Many modern cancer drugs target specific molecular alterations found across different tumor types. A drug approved to treat a BRAF mutation in melanoma, for instance, might also be tried in a thyroid cancer that carries the same mutation. The logic is rooted in the biology of the tumor, not just the organ where it started.
In a large-scale precision oncology program, off-label use of targeted therapies was most common in patients with thyroid cancer (about 9%) and breast cancer (about 8%). The most frequent molecular targets driving these prescriptions were alterations in BRCA1, BRCA2, ATM, ERBB2, and BRAF.5PubMed Central. Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program Compared with older chemotherapy agents that were often used interchangeably across cancer types based on clinical intuition, this newer approach is more targeted. Tumor genotyping gives doctors a biological rationale for using a drug off-label, but the clinical evidence to confirm it works in the new setting is often limited, and the drugs tend to be extremely expensive.6PubMed Central. Off-label use of targeted therapies in oncology
This is an area where the science is moving faster than regulatory approvals can keep up. Some countries have created “tumor-agnostic” approval pathways, allowing a drug to be used for any cancer carrying a specific mutation regardless of where the tumor originated. But many mutation-drug pairings still lack formal approval, leaving oncologists to prescribe off-label and patients to negotiate coverage.
When Off-Label Use Gets Risky
The key safety question is not whether a drug is being used on-label or off-label, but whether the off-label use is backed by solid evidence. A large study tracking adverse drug events found a meaningful difference depending on evidence quality. Off-label use that lacked strong scientific support had a notably higher rate of adverse events compared with on-label use. But off-label use that was backed by strong evidence showed essentially the same risk profile as on-label use.7JAMA Internal Medicine. Association of Off-label Drug Use and Adverse Drug Events in an Adult Population
That distinction is critical. “Off-label” is not a synonym for “experimental” or “dangerous.” Some off-label uses have decades of supporting evidence, while some recently approved on-label indications rest on a single pivotal trial. The label is a regulatory marker, not an automatic indicator of safety. The real risk emerges when a drug is prescribed off-label based on a hunch, anecdote, or a single case report rather than rigorous clinical data.
A practical challenge for patients is that there is no easy way to look at a prescription and know whether it is on- or off-label, let alone whether the off-label use is well-supported. Your pharmacist’s computer system may not flag it. Your insurance company may cover it without comment. The prescribing doctor may not mention it unless you ask. This silent quality of off-label use is part of why patient awareness matters.
What Patients Know (and Don’t Know)
Most patients have no idea off-label prescribing exists. In one study of primary care patients, over 96% had never heard of it. When the concept was explained to them, reactions were mixed but often wary: about 42% said they would not accept off-label treatment under any circumstances, and roughly 55% said they would never accept it for their children.8PubMed. Knowledge and attitudes of patients in primary care on off-label treatment
These numbers reveal a gap between clinical reality and patient expectations. Doctors prescribe off-label routinely, often with good reason, but patients are largely unaware it is happening. The same study found that patients tended to trust their primary care doctor more than hospital specialists on this issue: about 70% believed their family doctor would not expose them to off-label treatment, compared with only about 41% who felt the same confidence about hospital doctors. And if something went wrong, about half said they would consider legal action against the prescribing doctor.8PubMed. Knowledge and attitudes of patients in primary care on off-label treatment
This creates a tension. Informed consent is a legal and ethical requirement for any medical treatment, and several European courts have reinforced that the standard of disclosure should be determined by what the patient considers important, not just what the doctor deems worth mentioning.9PubMed. Off-label and unlicensed prescribing in Europe: implications for patients’ informed consent and liability If a patient would want to know that a drug is being used outside its approved indication, the doctor has an obligation to say so. In practice, this conversation does not always happen, partly because off-label prescribing is so normalized within medicine that many clinicians do not think of it as requiring special disclosure.
If you want to know whether your prescription is off-label, simply ask your doctor or pharmacist. It is a reasonable question, and the answer can help you make a more informed decision about the level of evidence behind your treatment.
Insurance, Cost, and the Reimbursement Maze
Whether your insurance covers an off-label prescription depends on your country, your insurer, and sometimes on how persistent your doctor is willing to be. In the United States, many insurers cover common off-label uses that are listed in standard drug compendia, but coverage is not guaranteed, and appeals may be needed. In countries with national health systems, the process can be even more bureaucratic.
A study of off-label reimbursement in Germany illustrates the friction. When doctors filed applications for coverage of off-label prescriptions with health insurers, only about 57% were approved on the first attempt. The approval rate climbed to 75% after up to two rounds of rejection and appeal. The median wait time just for the insurer to respond to the initial application was 49 days, and once coverage was finally granted, treatment did not start until a median of 92 days after the original request.10PubMed. Off-label prescriptions and decisions on reimbursement requests in Germany – a retrospective analysis For a patient with a serious or progressive condition, a three-month delay can be consequential.
In oncology, the financial stakes are particularly high. Targeted cancer therapies can cost tens of thousands of dollars per month, and an off-label prescription that an insurer declines to cover may put the drug entirely out of reach. Some countries have created compassionate use or expanded access programs to bridge this gap, but these vary widely in how accessible they actually are.11PubMed Central. On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients
Rare Diseases and the Orphan Drug Paradox
Off-label prescribing plays an outsized role in rare diseases. Many rare conditions have no approved treatment at all. When a drug does get approved for one rare disease under orphan drug legislation (which provides manufacturers with financial incentives like market exclusivity), it sometimes becomes the only game in town. If the drug shows promise for a related rare condition, prescribing it off-label is often the only practical option.
But this creates a strange dynamic. Once a drug is approved for one rare disease, the manufacturer has little incentive to run additional trials for other indications. The evidence from clinical use accumulates informally, but no one invests in the formal studies that would lead to label expansion. As one stakeholder in a Belgian qualitative study put it, companies see no reason to pursue new approvals when their product already dominates the market, and the evidence from real-world use is mounting anyway without any corporate investment in trials.12PubMed Central. Off-label use of orphan medicinal products: a Belgian qualitative study
Some orphan drugs end up being prescribed far more widely off-label than for their original approved condition. A well-known example involves the lidocaine patch, approved for a specific pain condition (post-herpetic neuralgia), which was widely prescribed off-label for all sorts of chronic pain. Modafinil, approved for narcolepsy, similarly saw extensive off-label use for general daytime sleepiness and fatigue. Both drugs were approved for narrow conditions that feature common, frustrating symptoms, so doctors were quick to try them for other patients struggling with similar problems.13PLoS ONE. The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs The orphan drug designation gave manufacturers the economic incentive to bring these drugs to market, but the real commercial payoff came from off-label prescribing for far more common conditions.
Legal Liability for Doctors
Off-label prescribing is legal, but it does not shield a doctor from malpractice liability. A physician who prescribes a drug off-label is held to the same standard of care as any other medical decision: they need to believe, based on available evidence and clinical judgment, that the prescription is in the patient’s best interest.14PubMed Central. Ten common questions (and their answers) about off-label drug use If a patient experiences harm and the prescribing decision was not supported by reasonable evidence, the doctor can face liability just as they would for any other clinical error.
The legal landscape varies by country. In many European jurisdictions, the informed-consent requirements are stricter for off-label prescribing. A doctor who fails to disclose the off-label nature of a prescription may face greater liability than one who disclosed it and obtained the patient’s agreement. In the United States, the legal framework is largely governed by state malpractice law, and courts generally ask whether a “reasonable physician” would have made the same prescribing decision under the circumstances. The key question in either system is the strength of the evidence, not the regulatory label itself.
How Hospitals Are Starting to Track Off-Label Use
One of the challenges with off-label prescribing is that, historically, no one has been systematically monitoring it. A drug is prescribed, dispensed, and taken, and unless someone specifically checks the indication against the label, the off-label nature of the prescription goes unrecorded. This makes it difficult to study outcomes, identify safety signals, or understand prescribing trends at scale.
Electronic health records are beginning to change this. Researchers have developed automated systems that cross-reference prescriptions with approved indications to flag potential off-label use. A systematic approach to detecting off-label prescribing in health records could enable better safety monitoring, reveal prescribing patterns, and support evaluation of real-world evidence.15PubMed Central. Hierarchical Concept Relations Improve Detection of Off-Label Drug Use in Electronic Health Records Data In pediatrics, where off-label rates are especially high, electronic health record data have already been used to estimate the risk of rare adverse events and compare outcomes between on-label and off-label use of the same medication.16PubMed. Electronic health record (EHR) based postmarketing surveillance of adverse events associated with pediatric off-label medication use
These tools are still relatively new and far from universal. Most clinics and pharmacies do not routinely flag off-label prescriptions for patients. But as electronic systems become more sophisticated and interoperable, the expectation is that off-label prescribing will become much more visible, both to individual patients and to the researchers and regulators who track drug safety after a medication reaches the market. That visibility could help separate the well-supported off-label uses from the poorly evidenced ones, which, as the adverse-event data suggest, is the distinction that actually matters for patient safety.